Vishnevsky A S, Shtofmakher J A, Bokhman J V, Tsyrlina E V, Bobrov J F, Chepick O F, Sofroniy D F
Petrov Research Institute of Oncology, Leningrad, USSR.
Clin Exp Obstet Gynecol. 1990;17(3-4):159-62.
The results of preoperative use of oxyprogesterone caproate (OPC), Tamoxifen and their combination in 165 patients suffering from primary endometrial carcinoma are presented. It was shown that Tamoxifen was able to increase concentrations cytoplasmatic receptors to progesterone in the tumor. The incidence of specific hormonal pathomorphosis in the tissue of the tumor in patients who received a combination of OPC and Tamoxifen was significantly higher (80% of cases) as compared to the separate use of OPC (60%) or Tamoxifen (57%).
本文呈现了165例原发性子宫内膜癌患者术前使用己酸羟孕酮（OPC）、他莫昔芬及其联合用药的结果。结果表明，他莫昔芬能够提高肿瘤细胞中孕激素的细胞质受体浓度。与单独使用OPC（60%）或他莫昔芬（57%）相比，接受OPC和他莫昔芬联合用药的患者肿瘤组织中特定激素病理形态的发生率显著更高（80%的病例）。
